Antitumor effects of combining metronomic chemotherapy with the antivascular action of ultrasound stimulated microbubbles

International Journal of Cancer

Volumn 132, Issue 12, 2013, Pages 2956-2966

  Todorova, Margarita ^a,b   Agache, Vlad ^b   Mortazavi, Omid ^b   Chen, Branson ^b   Karshafian, Raffi ^c   Hynynen, Kullervo ^a,b   Man, Shan ^b   Kerbel, Robert S ^b   Goertz, David E ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b Institute of Clinical Evaluative Sciences   (Canada)

^c RYERSON UNIVERSITY   (Canada)

Author keywords

antiangiogenic therapy; breast cancer; chemotherapy; microbubbles; neoadjuvant therapy; therapeutic ultrasound; vascular disrupting agent

Indexed keywords

CYCLOPHOSPHAMIDE; PERFLUTREN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ARTICLE; BLOOD FLOW; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG TRANSPORT; FEMALE; FLOW RATE; HUMAN; HUMAN CELL; IMAGE ANALYSIS; MICROBUBBLE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; TISSUE SECTION; TREATMENT RESPONSE; ULTRASOUND THERAPY;

ADMINISTRATION, METRONOMIC; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MICE; MICROBUBBLES; TUMOR BURDEN; ULTRASONIC THERAPY;

EID: 84876157238     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27977     Document Type: Article

References (49)

1. ter Haar GR,. High intensity focused ultrasound for the treatment of tumors. Echocardiography 2001; 18: 317-22.
2. Deckers R, Moonen CT,. Ultrasound triggered, image guided, local drug delivery. J Control Release 2010; 148: 25-33.
3. Unger EC, Porter T, Culp W, et al. Therapeutic applications of lipid-coated microbubbles. Adv Drug Deliv Rev 2004; 56: 1291-314.
4. Raymond SB, Skoch J, Hynynen K, et al. Multiphoton imaging of ultrasound/Optison mediated cerebrovascular effects in vivo. J Cereb Blood Flow Metab 2007; 27: 393-403.
5. Stieger SM, Caskey CF, Adamson RH, et al. Enhancement of vascular permeability with low-frequency contrast-enhanced ultrasound in the chorioallantoic membrane model. Radiology 2007; 243: 112-21.
6. Treat LH, McDannold N, Vykhodtseva N, et al. Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI-guided focused ultrasound. Int J Cancer 2007; 121: 901-7.
7. Ting CY, Fan CH, Liu HL, et al. Concurrent blood-brain barrier opening and local drug delivery using drug-carrying microbubbles and focused ultrasound for brain glioma treatment. Biomaterials 2012; 33: 704-12.
8. Zhao YZ, Lu CT, Zhou ZC, et al. Enhancing chemotherapeutic drug inhibition on tumor growth by ultrasound: an in vivo experiment. J Drug Target 2011; 19: 154-60.
9. Sorace AG, Warram JM, Umphrey H, et al. Microbubble-mediated ultrasonic techniques for improved chemotherapeutic delivery in cancer. J Drug Target 2012; 20: 43-54.
10. Miller DL,. Overview of experimental studies of biological effects of medical ultrasound caused by gas body activation and inertial cavitation. Prog Biophys Mol Biol 2007; 93: 314-30.
11. Hwang JH, Brayman AA, Reidy MA, et al. Vascular effects induced by combined 1-MHz ultrasound and microbubble contrast agent treatments in vivo. Ultrasound Med Biol 2005; 31: 553-64.
12. Hwang JH, Tu J, Brayman AA, et al. Correlation between inertial cavitation dose and endothelial cell damage in vivo. Ultrasound Med Biol 2006; 32: 1611-19.
13. Leighton T,. 1997 The acoustic bubbleed. London: Academic press Inc.
14. Wood AK, Bunte RM, Price HE, et al. The disruption of murine tumor neovasculature by low-intensity ultrasound-comparison between 1- and 3-MHz sonication frequencies. Acad Radiol 2008; 15: 1133-41.
15. Burke CW, Klibanov AL, Sheehan JP, et al. Inhibition of glioma growth by microbubble activation in a subcutaneous model using low duty cycle ultrasound without significant heating. J Neurosurg 2011; 114: 1654-61.
16. Goertz DE, Karshafian R, Hynynen K,. Investigating the effects of pulsed low intensity ultrasound and microbubbles in mouse tumors. In: IEEE International Ultrasonics Symposium Proceedings, Rome, Italy, 2009. 89-93.
17. Goertz DE, Karshafian R, Hynynen K,. Antivascular effects of pulsed low intensity ultrasound and microbubbles in mouse tumors. In: IEEE International Ultrasonics Symposium Proceedings, Beijing, China, 2008. 670-73.
18. Wood AK, Schultz SM, Lee WM, et al. Antivascular ultrasound therapy extends survival of mice with implanted melanomas. Ultrasound Med Biol 2010; 36: 853-7.
19. Tozer GM, Kanthou C, Baguley BC,. Disrupting tumour blood vessels. Nat Rev Cancer 2005; 5: 423-35.
20. Horsman MR, Siemann DW,. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 2006; 66: 11520-39.
21. Shaked Y, Ciarrocchi A, Franco M, et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006; 313: 1785-7.
22. Welford AF, Biziato D, Coffelt SB, et al. TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice. J Clin Invest 2011; 121: 1969-73.
23. Siemann DW, Shi W,. Dual targeting of tumor vasculature: combining avastin and vascular disrupting agents (CA4P or OXi4503). Anticancer Res 2008; 28: 2027-31.
24. Shaked Y, Kerbel RS,. Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy. Cancer Res 2007; 67: 7055-8.
25. Ferrara N, Kerbel RS,. Angiogenesis as a therapeutic target. Nature 2005; 438: 967-74.
26. Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60: 1878-86.
27. Kerbel RS, Kamen BA,. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004; 4: 423-36.
28. Daenen LG, Shaked Y, Man S, et al. Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models. Mol Cancer Ther 2009; 8: 2872-81.
29. Man S, Bocci G, Francia G, et al. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 2002; 62: 2731-5.
30. Emmenegger U, Shaked Y, Man S, et al. Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice. Mol Cancer Ther 2007; 6: 2280-9.
31. Shaked Y, Emmenegger U, Man S, et al. Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 2005; 106: 3058-61.
32. Krix M, Kiessling F, Vosseler S, et al. Comparison of intermittent-bolus contrast imaging with conventional power Doppler sonography: quantification of tumour perfusion in small animals. Ultrasound Med Biol 2003; 29: 1093-103.
33. Fenton BM, Paoni SF, Lee J, et al. Quantification of tumour vasculature and hypoxia by immunohistochemical staining and HbO2 saturation measurements. Br J Cancer 1999; 79: 464-71.
34. Duan WR, Garner DS, Williams SD, et al. Comparison of immunohistochemistry for activated caspase-3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC-3 subcutaneous xenografts. J Pathol 2003; 199: 221-8.
35. Treat LH,. Impact of focused ultrasound-enhanced drug delivery on survival in rats with glioma. 2009.
36. Lin CY, Tseng HC, Shiu HR, et al. Ultrasound sonication with microbubbles disrupts blood vessels and enhances tumor treatments of anticancer nanodrug. Int J Nanomedicine 2012; 7: 2143-52.
37. Minchinton AI, Tannock IF,. Drug penetration in solid tumours. Nat Rev Cancer 2006; 6: 583-92.
38. McDannold NJ, Vykhodtseva NI, Hynynen K,. Microbubble contrast agent with focused ultrasound to create brain lesions at low power levels: MR imaging and histologic study in rabbits. Radiology 2006; 241: 95-106.
39. Rai R, Richardson C, Flecknell P, et al. Study of apoptosis and heat shock protein (HSP) expression in hepatocytes following radiofrequency ablation (RFA). J Surg Res 2005; 129: 147-51.
40. Hu Z, Yang XY, Liu Y, et al. Investigation of HIFU-induced anti-tumor immunity in a murine tumor model. J Transl Med 2007; 5: 34.
41. Chen H, Kreider W, Brayman AA, et al. Blood vessel deformations on microsecond time scales by ultrasonic cavitation. Phys Rev Lett 2011; 106: 034301.
42. Klotz AR, Lindvere L, Stefanovic B, et al. Temperature change near microbubbles within a capillary network during focused ultrasound. Phys Med Biol 2010; 55: 1549-61.
43. Pasquier E, Kavallaris M, Andre N,. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 2010; 7: 455-65.
44. Chappell JC, Klibanov AL, Price RJ,. Ultrasound-microbubble-induced neovascularization in mouse skeletal muscle. Ultrasound Med Biol 2005; 31: 1411-22.
45. Song J, Qi M, Kaul S, et al. Stimulation of arteriogenesis in skeletal muscle by microbubble destruction with ultrasound. Circulation 2002; 106: 1550-5.
46. Yoshida J, Ohmori K, Takeuchi H, et al. Treatment of ischemic limbs based on local recruitment of vascular endothelial growth factor-producing inflammatory cells with ultrasonic microbubble destruction. J Am Coll Cardiol 2005; 46: 899-905.
47. Wu F, Chen WZ, Bai J, et al. Tumor vessel destruction resulting from high-intensity focused ultrasound in patients with solid malignancies. Ultrasound Med Biol 2002; 28: 535-42.
48. Hynynen K, Chung AH, Colucci V, et al. Potential adverse effects of high-intensity focused ultrasound exposure on blood vessels in vivo. Ultrasound Med Biol 1996; 22: 193-201.
49. Quesson B, Merle M, Kohler MO, et al. A method for MRI guidance of intercostal high intensity focused ultrasound ablation in the liver. Med Phys 2010; 37: 2533-40.